Cases from the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients with Genitourinary Cancers


Cases from the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients with Genitourinary Cancers
Proceedings from a CME symposium held at the 2018 Genitourinary Cancers Symposium. Featuring perspectives from Drs Charles G Drake, Peter H O’Donnell, Elizabeth R Plimack, Thomas Powles and David I Quinn.
2.5 AMA PRA Category 1 Credits
To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CME credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Introduction

Current and Future Integration of Immune Checkpoint Inhibitors into the Management of Urothelial Bladder Cancer (UBC)

Existing and Emerging Role of Anti-PD-1/PD-L1 Antibodies in Renal Cell Carcinoma (RCC)

Clinical Trials of Immune Checkpoint Inhibition in Prostate Cancer (PC)

Patterns and Predictors of Response to Immune Checkpoint Inhibitors 

Incidence and Management of Toxicities Associated with Immune Checkpoint Inhibitors; Autoimmune Contraindications to Treatment